Compare RIVN & GEHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RIVN | GEHC |
|---|---|---|
| Founded | 2009 | 1892 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto Manufacturing | Computer Software: Prepackaged Software |
| Sector | Consumer Discretionary | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.0B | 27.9B |
| IPO Year | 2021 | 2022 |
| Metric | RIVN | GEHC |
|---|---|---|
| Price | $16.38 | $62.55 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 21 | 13 |
| Target Price | $17.74 | ★ $88.38 |
| AVG Volume (30 Days) | ★ 37.4M | 4.7M |
| Earning Date | 04-30-2026 | 04-29-2026 |
| Dividend Yield | N/A | ★ 0.24% |
| EPS Growth | ★ 34.54 | 4.84 |
| EPS | N/A | ★ 0.85 |
| Revenue | $5,387,000,000.00 | ★ $20,625,000,000.00 |
| Revenue This Year | $36.51 | $7.12 |
| Revenue Next Year | $63.08 | $4.45 |
| P/E Ratio | ★ N/A | $71.91 |
| Revenue Growth | ★ 8.39 | 4.84 |
| 52 Week Low | $11.57 | $58.75 |
| 52 Week High | $22.69 | $89.77 |
| Indicator | RIVN | GEHC |
|---|---|---|
| Relative Strength Index (RSI) | 47.45 | 47.64 |
| Support Level | $14.26 | $60.17 |
| Resistance Level | $17.97 | $65.83 |
| Average True Range (ATR) | 0.96 | 1.87 |
| MACD | -0.20 | -0.23 |
| Stochastic Oscillator | 21.38 | 39.03 |
Rivian is a battery electric vehicle automaker that sells its vehicles in the US and Canada. The company also develops electronic control units and related software for autos in a joint venture with Volkswagen. Rivian has multiple vehicles in its fleet, which include a luxury truck and full-size SUV and a delivery van. The company plans to begin selling a midsize SUV in 2026. Total deliveries were over 42,000 in 2025. Rivian is also developing autonomous driving software to be used in its vehicles and for robotaxis on the Uber ride-hailing network.
GE HealthCare Technologies is a leading medical technology firm with leading market share in imaging and ultrasound equipment. The company reports four major segments: imaging (45% of revenue), advanced visualization solutions (26%), patient care solutions (15%), and pharmaceutical diagnostics (14%). The company's sales are geographically diverse, with the United States, EMEA, China, and the rest of the world accounting for 46%, 26%, 11%, and 17%, respectively. We estimate approximately half of its revenue is recurring, which consists of servicing (about one-third of revenue), pharmaceutical diagnostics (about 10%-15%), and digital solutions (just over 5%).